Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Urinary Bladder Neoplasms 5Muscle Invasive Bladder Cancer (MIBC) 2Kidney Neoplasms 2Upper Tract Urinary Carcinoma 1Penile Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Muscle-invasive Bladder Urothelial Carcinoma 1Muscle Invasive Bladder Cancer 1Melanoma 1Liver Neoplasms 1High-risk Renal Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma in Situ 1Advanced Urothelial Carcinoma 1Advanced Renal Cell Carcinoma (RCC) 1

Interventions

toripalimab 2zanidatamab 1tislelizumab 1disitamab vedotin 1Probiotics 1Gemcitabine 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Cancer (MIBC) × toripalimab × Genitourinary × Clear all
NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
146 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT07201675 2025-10-01

Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting
59 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡